# Neurometabolic profiles of autism spectrum disorder patients with genetic variants in specific neurotransmission and synaptic genes

**Authors:** Joana Vilela, Andreia C. Pereira, Inês R. Violante, Susana Mouga, Célia Rasga, João Xavier Santos, Hugo Martiniano, Ana Rita Marques, Guiomar Oliveira, Miguel Castelo-Branco, Astrid Moura Vicente

PMC · DOI: 10.1038/s41598-025-20090-x · Scientific Reports · 2025-10-17

## TL;DR

This study links genetic variants in neurotransmission and synaptic genes to altered brain metabolism in autism patients, focusing on GABA and glutamate pathways.

## Contribution

The study integrates genetic variants with neurometabolic profiles to identify specific pathways affected in autism.

## Key findings

- 12 damaging genetic variants were found in 12 NS genes in 10 ASD individuals.
- ASD patients with NS gene variants showed lower tCr and tNAA levels compared to controls.
- Altered metabolism is linked to dysfunction in glutamatergic and GABAergic pathways.

## Abstract

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by impaired social interaction, and restricted and repetitive patterns of behavior. ASD presents as a clinical spectrum, with variable levels of severity and multiple co-occurring conditions. The etiology of ASD may involve hundreds of genes and there is evidence that neurotransmitter and synaptic (NS) pathways are implicated. Proton Magnetic Resonance Spectroscopy (1H-MRS) has made it possible to study the concentration of brain neurometabolites and compare their levels in the brains of ASD and control individuals. We integrated genetic variants in NS genes with 1H-MRS analysis, and identified 12 predicted damaging variants (PDVs) in 12 NS genes in 10 ASD individuals, most mapping to genes involved in Gamma-aminobutyric acid (GABA) and glutamate pathways. Total creatine (tCr) and total N-acetyl aspartate (tNAA), markers of bioenergetics and neuronal metabolism, respectively, were lower in ASD patients with genetic alterations in NS genes compared to a control group without ASD. We conclude that PDVs in NS genes that are important for the regulation of glutamate or involved in GABAergic functions are associated with neurometabolic alterations, and that dysfunction in glutamatergic and/or GABAergic pathways may be implicated as these pathways are linked to the metabolic measures altered in cases.

The online version contains supplementary material available at 10.1038/s41598-025-20090-x.

## Linked entities

- **Chemicals:** glutamate (PubChem CID 611)

## Full-text entities

- **Diseases:** ASD (MESH:D000067877), neurometabolic alterations (MESH:D004408), social interaction (MESH:C563663), neurodevelopmental condition (MESH:D020763)
- **Chemicals:** 1H (-), creatine (MESH:D003401), N-acetyl aspartate (MESH:C000179), GABA (MESH:D005680), glutamate (MESH:D018698)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12534664/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12534664/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12534664/full.md

---
Source: https://tomesphere.com/paper/PMC12534664